NCT03535298

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 800 (estimated)
• Sponsor: The Cleveland Clinic · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding the decision for medication approval by third parties.

Conditions

• Multiple Sclerosis, Relapsing-Remitting

Interventions

Type	Name	Description
DRUG	Early Highly Effective Therapies Group	Highly Effective MS Therapy group of medications
DRUG	Escalation Therapies Group	Escalation MS Therapy group of medications

Timeline

• Start date: 2019-01-03
• Primary completion: 2027-07-30
• Completion: 2027-07-30
• First posted: 2018-05-24
• Last updated: 2025-08-28

Locations

30 sites across 2 countries: United States, United Kingdom

Regulatory

• FDA-regulated drug study